Compare Exelixis Inc. Common Stock (EXEL) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $59.77 (market cap $14.62B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Exelixis Inc. Common Stock is the larger of the two by market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Halozyme Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 1 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| EXEL | HALO | |
|---|---|---|
Market Cap | $14.62B | $12.58B |
Volume | 2,684,957 | 2,179,278 |
Sector | Health | Health |
52-Week High | $59.13 | $115.22 |
52-Week Low | $34.54 | $61.63 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $13.95B | $14.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
